Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of Nalbuphine After Intravenous and Intranasal Administration in Infants

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infants 29 days-3 months~* Minimum Body weight 3.0 kg~* Indications: septical work up~* Parent has been informed about the study and has signed Informed Consent Form~Exclusion Criteria:~* Infants who were born prematurely (before 37 weeks gestation)~* Known kidney or liver disease~* Known chronic illness~* Documented previous adverse reaction to nalbuphine~* Treatment with a depressant drug within 5 days prior to study~* Epistaxis, nose trauma (only for the intranasal application)~* Barriere of language

- Gender: ALL
- Minimum Age: 29 Days
- Maximum Age: 3 Months
- Healthy Volunteers: f

Study Arms:
- intravenous (Type: ACTIVE_COMPARATOR): single iv application of nalbuphine 0.05mg/kg
- intranasal (Type: ACTIVE_COMPARATOR): single intranasal application of nalbuphine 0.1mg/kg in infants.

Based on this trial design, predict the completion outcome and termination type (if applicable).